yes, I do. ApoB=72, and rest below. BTW I’m lucky my LPa is a very desirable 13. So, not going to have a CVD event anytime soon, and most likely NEVER LOL.
. . . puts more than half of the MACE risk into a single tracking metric with (as thought contemporaneously) no loss and some benefit.
Not covered in this metric are conditions exemplified by a person with “perfect” lipid metrics drops dead of a MACE. A few of those cases await explanation or involve unusual, one-off circumstances but most of them involve long term high systemic inflammation. I’m very close to concluding that inflammation, rather than being an accelerant of MACE, is actually in the causal chain. Making this case, however, involves many arguments and footnotes. For now, it seem certain sustained elevated inflammation strongly exacerbates MACE. What to track? GlycA covers more of your risk bases than other inflammation metrics.
RW-ApoB and GlycA low? If yes, monitor and move on to something else.